CRON Stock Analysis: Cronos | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 1.249m USD | 12M Return: 29.6% | CA22717L1013 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.07M
Qual. Beats: 0
Rev. Trend: 96.0%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Cronos Group Inc. (NASDAQ: CRON) is a Canadian cannabinoid company engaged in the cultivation, production, distribution, and marketing of cannabis products across Canada, Israel, and select international markets. Its product portfolio spans dried flower, pre-rolls, oils, vaporizers, edibles, and tinctures, marketed under brands including Spinach, Lord Jones, Lit, and Peace Naturals. The company is headquartered in Stayner, Canada, and is classified within the Health Care sector (Pharmaceuticals sub-industry), reflecting the industrys positioning at the intersection of consumer wellness and pharma-adjacent therapeutics. Canada legalized recreational cannabis nationwide in October 2018, providing a regulated domestic framework that has supported the growth of federally licensed producers like Cronos, while the companys international footprint, notably in Israel, reflects the cross-border regulatory patchwork that shapes the global cannabis industry.
- Altria strategic review could reshape ownership structure
- Canadian recreational cannabis pricing competition squeezes gross margins
- International expansion into Israel and Germany accelerates revenue diversification
| Net Income: 69.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 4.58 > 1.0 |
| NWC/Revenue: 352.4% < 20% (prev 682.8%; Δ -330.4% < -1%) |
| CFO/TA 0.05 > 3% & CFO 54.9m > Net Income 69.8m |
| Net Debt (-795.7m) to EBITDA (39.5m): -20.13 < 3 |
| Current Ratio: 16.18 > 1.5 & < 3 |
| Outstanding Shares: last quarter (385.3m) vs 12m ago 0.0% < -2% |
| Gross Margin: 33.54% > 18% (prev 32.74%; Δ 0.80% > 0.5%) |
| Asset Turnover: 20.62% > 50% (prev 11.09%; Δ 9.54% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.73 (Total Current Assets 912.0m - Total Current Liabilities 56.4m) / Total Assets 1.18b |
| B: 0.42 (Retained Earnings 492.3m / Total Assets 1.18b) |
| C: 0.02 (EBIT TTM 25.2m / Avg Total Assets 1.18b) |
| D: 17.12 (Book Value of Equity 1.07b / Total Liabilities 62.4m) |
| Altman-Z'' = 24.24 = AAA |
| DSRI: 0.71 (Receivables 52.1m/39.4m, Revenue 242.8m/130.3m) |
| GMI: 0.98 (GM 32.74% / 33.54%) |
| AQI: 1.29 (AQ_t 0.11 / AQ_t-1 0.08) |
| SGI: 1.86 (Revenue 242.8m / 130.3m) |
| TATA: 0.01 (NI 69.8m - CFO 54.9m) / TA 1.18b) |
| Beneish M = -2.49 (Cap -4..+1) = BBB |
As of September 03, 2026, the stock is trading at USD 3.24 with a total of 847,599 shares traded. Over the past week, the price has changed by -8.73%, over one month by +14.49%, over three months by +18.68% and over the past year by +29.60%.
Current recommended Stop Loss: 3.10 (which is 4.3% or 1.3 ATR below the current price).
Cronos has received a consensus analysts rating of 3.40. Therefore, it is recommended to hold CRON.
- StrongBuy: 1
- Buy: 1
- Hold: 2
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 2.5 | -21.9% |
P/E Trailing = 17.8421
P/E Forward = 21.4592
P/S = 6.9738
P/B = 1.2255
Revenue TTM = 242.8m USD
EBIT TTM = 25.2m USD
EBITDA TTM = 39.5m USD
Long Term Debt = 1.13m USD (estimated: total debt 1.29m - short term 162k)
Short Term Debt = 162k USD (from shortTermDebt, last quarter)
Debt = 1.29m USD (from shortLongTermDebtTotal, last quarter) (leases 1.29m already included)
Net Debt = -795.7m USD (calculated: Debt 1.29m - CCE 797.0m)
Enterprise Value = 453.2m USD (1.25b + Debt 1.29m - CCE 797.0m)
Interest Coverage Ratio = unknown (Ebit TTM 25.2m / Interest Expense TTM 0.0)
EV/FCF = 10.17x (Enterprise Value 453.2m / FCF TTM 44.5m)
FCF Yield = 9.83% (FCF TTM 44.5m / Enterprise Value 453.2m)
FCF Margin = 18.34% (FCF TTM 44.5m / Revenue TTM 242.8m)
Net Margin = 28.74% (Net Income TTM 69.8m / Revenue TTM 242.8m)
Gross Margin = 33.54% ((Revenue TTM 242.8m - Cost of Revenue TTM 161.4m) / Revenue TTM)
Gross Margin QoQ = 40.30% (prev 41.42%)
Tobins Q-Ratio = 0.38 (Enterprise Value 453.2m / Total Assets 1.18b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 1.29m)
Taxrate = 0.14% (51.0k / 35.7m)
NOPAT = 25.2m (EBIT 25.2m * (1 - 0.14%))
Current Ratio = 16.18 (Total Current Assets 912.0m / Total Current Liabilities 56.4m)
Debt / Equity = 0.00 (Debt 1.29m / totalStockholderEquity, last quarter 1.07b)
Debt / EBITDA = -20.13 (Net Debt -795.7m / EBITDA 39.5m)
Debt / FCF = -17.86 (Net Debt -795.7m / FCF TTM 44.5m)
Total Stockholder Equity = 1.08b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.93% (Net Income 69.8m / Total Assets 1.18b)
RoE = 6.46% (Net Income TTM 69.8m / Total Stockholder Equity 1.08b)
RoCE = 2.33% (EBIT 25.2m / Capital Employed (Equity 1.08b + L.T.Debt 1.13m))
RoIC = 2.27% (NOPAT 25.2m / Invested Capital 1.11b)
WACC = 8.21% (E(1.25b)/V(1.25b) * Re(8.22%) + D(1.29m)/V(1.25b) * Rd(0.0%) * (1-Tc(0.00)))
Discount Rate = 8.22% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 49.75 | Cagr: 0.45%
[DCF] Terminal Value 75.44% ; FCFF base≈44.5m ; Y1≈44.7m ; Y5≈47.4m
[DCF] Fair Price = 4.16 (EV 736.9m - Net Debt -795.7m = Equity 1.53b / Shares 368.4m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.28 | # QB: 0
Revenue Correlation: 96.04 | Revenue CAGR: 44.23% | SUE: 0.46 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.04 | Chg30d=N/A | Revisions=-25% | Analysts=2
EPS current Year (2026-12-31): EPS=0.22 | Chg30d=+68.16% | Revisions=-40% | GrowthEPS=+906.8% | GrowthRev=+39.0%
EPS next Year (2027-12-31): EPS=0.16 | Chg30d=+7.18% | Revisions=-40% | GrowthEPS=-28.3% | GrowthRev=+15.8%
[Analyst] Revisions Ratio: -62% (up=0, down=5)